Hence an attractive alternative would be an ideal selective progesterone receptor modulator (SPRM) or so-called mesoprogestin that would control the bleeding irregularities of MirenaTM or similar drugs without inducing unopposed estrogenicity in the endometrium would be beneficial to treat endometriosis and perhaps early stage endometrial cancer. Here, PGR is linked to endometrial cancer.